Evidence status: external analytical/clinical-methods publication; not an AIRCHILL study, not a cleared field diagnostic, and not evidence that respiratory cooling benefits traumatic brain injury.

What is new

A peer-reviewed study published 4 September 2026 evaluated a dried-plasma biosampling lateral-flow device for traumatic-brain-injury biomarkers. The device accepts approximately 50–70 µL capillary blood, separates plasma onto a dry strip and was tested with GFAP, UCH-L1, NfL and Tau. Dried-sample measurements correlated strongly with matched wet plasma in an archived geriatric TBI cohort, and a second adult TBI cohort showed proof-of-principle discrimination of CT-positive cranial lesions. Signal recovery declined with prolonged room-temperature or high-temperature storage, so this remains a sample-handling technology under evaluation rather than a validated diagnostic endpoint.

Why it matters for MedicalCooling

For any future AIRCHILL TBI or neurotrauma programme, one practical barrier is obtaining time-resolved neuroinjury biomarkers in ambulances, emergency departments and distributed trauma networks without adding a full venous-processing and cold-chain workflow. A validated dried-capillary format could eventually reduce that burden and make serial biomarker collection easier across prehospital and hospital phases.

Protocol decision: do not adopt the device as a clinical endpoint or eligibility test yet. Track it as an enabling sampling technology. If an AIRCHILL TBI feasibility protocol is developed, a nested methods substudy could compare capillary dried plasma with the laboratory reference matrix and preserve exact sampling times, storage temperature and elapsed storage time.

Source and evidence boundary

Kobeissy F, Elbayoumi E, Arja RD, et al. Evaluation of a novel high-capacity dry plasma biosampling-lateral flow device for the testing of traumatic brain injury protein biomarkers. Journal of Advanced Research. Published 4 September 2026. PMID 42697480. DOI 10.1016/j.jare.2026.09.003. PubMed record.

This update changes trial-operations intelligence only. It does not change AIRCHILL efficacy assumptions, TBI effect-size assumptions, regulatory claims or current patient-use status.

Frist: ESICM Call 2 is open as of 7 September 2026 and closes 5 October 2026.

The European Society of Intensive Care Medicine invites members and working groups to propose guidelines, consensus statements, position papers and other scientific documents with strong ICU relevance, robust methodology and alignment with ESICM priorities.

MedicalCooling / Ethical Saving relevance: this is not a product-promotion or direct funding route. A credible use would be to work with an eligible ESICM member or section on a product-independent scientific question where evidence is limited or inconsistent—for example data standards and trial-design principles for very early neuroprotection, temperature-control exposure, ventilation co-interventions and EMS-to-ICU handover. The scope should remain broader than AIRCHILL and include external experts and competing approaches where appropriate.

Next action: identify an ESICM member/working group with relevant resuscitation, neurocritical-care or ventilation expertise and decide promptly whether a neutral consensus proposal is sufficiently mature for the 5 October deadline.

Source: European Society of Intensive Care Medicine, 2026 Call for Applications – Guidelines, Consensus Statements and Position Papers.

Evidence status: external registry and regulatory-development intelligence. These records do not establish AIRCHILL safety or efficacy.

VENT-SIM: ventilation performance becomes an explicit human-factors benchmark

The University of Texas Southwestern Medical Center and the American Heart Association are recruiting the VENT-SIM randomized crossover simulation study (NCT07352709; ClinicalTrials.gov record updated 3 September 2026). It tests real-time visual feedback during CPR and compares ventilation during 30:2 versus continuous-compression strategies. The primary outcome is the proportion of ventilations within the protocol target of 500–600 mL; inspired/expired volume and ventilation rate are secondary measures.

AIRCHILL implication: EMS human-factors and intra-arrest simulations should preserve delivered and expired tidal volume, ventilation rate, ventilation-target adherence and the CPR strategy in use. Cooling controls and feedback must be shown not to degrade the ventilation task.

Peri-EVT CO₂ modulation: PaCO₂ is a co-intervention, not background noise

NCT05051397, updated 3 September 2026, is prospectively testing moderate hypercapnia versus normocapnia during mechanically ventilated thrombectomy to influence collateral cerebral perfusion. Because CO₂ is a potent cerebral vasodilator, the AIRCHILL-STROKE programme now treats PaCO₂/EtCO₂ target, serial exposure and deviations as prespecified co-intervention variables.

AIRCHILL implication: a respiratory-cooling effect should not be confounded by systematic differences in ventilation-related CO₂ exposure between treatment groups.

CHILL-AP and Arctx: a useful regulatory and platform-development comparator

The CHILL-AP study (NCT07698119; record updated 3 September 2026) plans a 200-patient multicentre randomized trial of the Arctx Cool Catheter Set plus standard care versus standard care in acute pancreatitis. The catheter is connected to a commercial Blanketrol III heat-exchange system. The trial is described as supporting a future FDA marketing submission. Separately, the Arctx Cool Catheter Set received US 510(k) clearance K250632 in 2025 as a Class II esophageal thermal-regulation and gastric-suction device.

AIRCHILL implication: the programme can use this as an external development benchmark for two principles already central to AIRCHILL: reuse qualified platform hardware where appropriate, and keep performance/temperature-management evidence distinct from a later disease-specific clinical outcome claim. This does not establish predicate equivalence, Freedom to Operate or AIRCHILL’s regulatory route.

What changed on MedicalCooling.com

• The cardiac-arrest CIP, SoA/CRF and human-factors pipeline now capture CPR ventilation strategy, inspired/expired volume and real-time feedback as explicit operational variables.
• The stroke CIP, SAP and SoA/CRF now prespecify PaCO₂/EtCO₂ exposure and deviations as a peri-EVT co-intervention.
• The translational pipeline now records CHILL-AP/Arctx as an external platform/regulatory-development comparator with explicit non-equivalence caveats.
• The research register contains a dated live-intelligence addendum while preserving the older frozen corpus snapshot.

Sources: ClinicalTrials.gov NCT07352709, NCT05051397 and NCT07698119; US FDA 510(k) K250632. Registry status is sponsor-submitted and may change.

Strategic developments

Several 2026 technology and market signals are relevant to AIRCHILL positioning.

NeuroIntact / VCool

NeuroIntact is developing a portable intranasal gas-cooling platform. Its patent family and clinical-development activity make it relevant for future freedom-to-operate review, particularly around thermoelectric cooling, gas-path control, sensor feedback and intranasal delivery.

BrainCool / ZOLL

BrainCool continues to expand temperature-management commercialisation with ZOLL and remains an important reference platform for clinical evidence, distribution, recurring consumables and international regulatory expansion.

corpuls auryx

The new in-ear sensor platform combining temperature, pulse and oxygen saturation is strategically interesting for EMS interoperability. Established monitoring and telemedicine components may allow AIRCHILL to integrate mature external technology rather than reinvent every subsystem.

Orixha / LunCoLive

Total liquid ventilation remains a technologically distinct route to rapid cooling. Its complexity and clinical-development path make it both a useful comparator and a reminder that respiratory heat exchange can be pursued through very different architectures.

IP implication

AIRCHILL’s granted patent position does not remove the need for product-level freedom-to-operate analysis. Claim charts should be maintained against emerging patent families, especially where competitors combine cooled gas, airway delivery, thermoelectric hardware, feedback control and temperature sensing.

Product-strategy implication

Differentiation should remain focused on:

• very early use in time-critical care,
• integration with transport ventilation,
• controlled respiratory heat exchange,
• modular use of established monitoring/OEM components,
• a clearly measured safety and clinical-validation pathway.

Competitor references are provided for strategic monitoring and do not imply infringement, invalidity or freedom to operate.

Current opportunity set

MedicalCooling and EthicalSaving are tracking several time-sensitive programmes that could accelerate AIRCHILL development, validation and market access.

High-priority opportunities

• MEDICA Healthcare Innovation World Cup / MEDICA START-UP COMPETITION: international visibility, investors and strategic-industry contacts for medical-device startups.
• CO-AX / Sahlgrenska Science Park: MedTech and life-science acceleration with clinical, regulatory, reimbursement and investor access.
• Osnabrück Healthcare Accelerator (OHA): German MedTech programme with support around certification, reimbursement and business development.
• KMU-innovativ Medizintechnik: potential German R&D funding for technical and preclinical development.
• EIC Accelerator: major European scale-up instrument for sufficiently mature innovation projects.
• Innowwide / Eurostars: international market-feasibility and cross-border R&D routes where eligibility and project maturity fit.
• G-BA Innovationsfonds: potentially relevant for care-pathway, implementation and health-economic research rather than pure device development.

Clinical and industry networking

Relevant 2026 routes also include ERC Resuscitation, Charité acute/emergency medicine networks, MEDICA, EMS research fellowships and OEM ecosystems around ventilation, monitoring, defibrillation, telemedicine and airway systems.

Why this matters

The optimal AIRCHILL financing stack is unlikely to come from a single source. A staged combination of grant funding, clinical collaborations, accelerators, strategic OEM relationships and later venture or EIC capital can reduce dilution while building the evidence required for regulatory and commercial milestones.

Next-action principle

Each programme should be screened against:

• applicant eligibility,
• TRL and clinical maturity,
• funding versus equity terms,
• permitted clinical work,
• geographic restrictions,
• access to hospitals or EMS partners,
• regulatory support,
• deadline and preparation burden.

This page records strategic opportunities; it does not imply acceptance into, endorsement by or funding from any listed programme.

What changed

Several 2026 developments materially affect future MedicalCooling market access:

• Germany’s emergency-care reform is moving toward recognising medical emergency rescue as a distinct statutory-health-insurance service rather than merely transport.
• The G-BA Innovationsfonds is becoming more constrained from 2027, increasing the value of remaining 2026 application windows.
• The EU HTA framework now offers Joint Scientific Consultation pathways for selected high-risk medical devices, allowing evidence requirements to be discussed before pivotal studies.
• The UK has strengthened value-based procurement for MedTech, putting more emphasis on outcomes, efficiency and total pathway cost rather than purchase price alone.
• CMS continues to provide hospital new-technology payment pathways such as NTAP, while ambulance reimbursement remains a separate US workstream.

Why this matters for AIRCHILL

AIRCHILL should not generate clinical evidence first and design reimbursement evidence later. Clinical, regulatory, HTA and health-economic endpoints should be aligned from the start.

Recommended development implication

The programme should capture, where feasible:

• neurological outcome,
• ICU length of stay,
• ventilation duration,
• rehabilitation utilisation,
• long-term care burden,
• device and consumable cost,
• EMS workflow time and staffing,
• hospital resource use.

This enables one evidence programme to support clinical validation, CE/FDA strategy, HTA, procurement and payer discussions.

Primary institutions to monitor: German Bundestag/BMG, G-BA, European Commission HTA Coordination Group, NICE/NHS, CMS.

AIRCHILL remains a development-stage technology and no reimbursement pathway described here constitutes current coverage for AIRCHILL.

What changed

In August 2026 the US FDA published Class II recalls affecting temperature-management systems including Blanketrol II Model 222S and Innercool CoolBlue Model STx. The reported issue involved possible overheating of a CPU board followed by loss of device function during temperature therapy.

Why this matters for AIRCHILL

This is not evidence against temperature management. It is directly relevant to device risk management and architecture. A future AIRCHILL system should explicitly address loss of cooling performance, thermal or electronic component overheating, alarm behaviour, safe shutdown and continued ventilation if the cooling subsystem fails.

Engineering and regulatory implication

These scenarios should be reflected in ISO 14971 risk management, FMEA/FMECA and verification planning, including:

• cooling-function loss,
• controller/CPU overheating,
• sensor or control-loop failure,
• alarm latency and alarm visibility,
• safe fallback temperature behaviour,
• separation of ventilation-critical and cooling-critical functions where appropriate,
• recovery and alternative-treatment procedures.

Source: US Food and Drug Administration, August 2026 recall notices. https://www.fda.gov/

AIRCHILL is a development-stage technology with no FDA clearance or CE mark.

What changed

A 2026 pilot randomized trial in Critical Care Medicine compared targeted temperature management at 35 °C with controlled normothermia at 37 °C after heatstroke stabilisation. The trial did not show a meaningful functional or survival benefit for induced hypothermia and reported more severe gastrointestinal injury, arrhythmias and treatment for shivering in the 35 °C group.

Why this matters for MedicalCooling

The result sharpens the heatstroke indication strategy. The strongest rationale remains rapid removal of excess heat and minimising time in dangerous hyperthermia. It does not support routinely extending cooling into induced hypothermia after stabilisation.

Study-design implication

A future AIRCHILL heatstroke programme should prioritise:

• cooling rate in °C/min,
• time to below 40 °C and to a defined safe target range,
• cumulative time above critical temperature thresholds,
• organ-function trajectory,
• arrhythmias and gastrointestinal safety,
• shivering and sedation burden.

Source: Critical Care Medicine / PubMed, August 2026.

AIRCHILL remains a development-stage technology. External evidence is used to define testable study questions, not to claim established efficacy.

What changed

The ICECAP randomized clinical trial was published in JAMA in August 2026. In 1,158 comatose out-of-hospital cardiac-arrest patients who had reached below 34 °C within four hours, extending hypothermia at 33 °C did not improve neurological outcome, mortality or the key secondary outcomes.

Why this matters for AIRCHILL

This result does not answer the AIRCHILL question of very early respiratory cooling versus later or conventional temperature management. ICECAP primarily tests duration after hypothermia has already been achieved. For AIRCHILL, timing, cooling rate, route, temperature depth, duration, thermal distribution and rewarming therefore need to remain separate study variables.

Development implication

The clinical programme should avoid treating “temperature” as a single intervention. Future feasibility and randomized studies should prespecify:

• time from collapse/ROSC to first cooling,
• time to target temperature,
• core versus local thermal effect,
• duration of cooling,
• rewarming profile,
• neurological outcome.

Source: JAMA, ICECAP trial, August 2026. https://jamanetwork.com/

AIRCHILL remains a development-stage technology. External trial results provide context and do not establish AIRCHILL efficacy.